INTRODUCTION
Rotaviruses, which form one genus of the family Reoviridae, are now recognized as the most important cause of severe viral gastroenteritis in humans and animals (see references 75, 100, 107, 147, 149 , and 173 for reviews). These viral pathogens are more diverse than was originally thought, and this review highlights information learned during the past 5 years on the classification, biology, gene expression, and pathogenesis of the rotaviruses. Historical, epidemiological, and clinical features of rotavirus infections, methods of virus detection, and details of the replication cycle are considered only if they report significant new 
ROTAVIRUS GENE STRUCTURE AND FUNCTION

ROTAVIRUS CHARACTERISTICS AND CLASSIFICATION
Morphologic and biochemical characteristics shared by members of the rotavirus genus include the following: (i) mature virus particles are nonenveloped and possess a multilayered icosahedral protein capsid, approximately 75 nm in diameter, composed of an outer layer, an inner layer, and a core; (ii) the virus genome consists of 11 segments of double-stranded RNA (dsRNA); (iii) particles contain an RNA-dependent RNA polymerase and other enzymes capable of producing capped RNA transcripts; (iv) virus replication occurs in the cytoplasm of infected cells; (v) the viruses are capable of genetic reassortment; (vi) virus cultivation in vitro is facilitated by treatment with proteolytic enzymes, which enhances infectivity by cleavage of the outer capsid polypeptide VP4; (vii) virus particles are formed by budding into the endoplasmic reticulum (ER), and enveloped particles are evident transiently at this stage of morphogenesis; and (viii) mature particles are liberated from infected cells by cell lysis. Only a few of the numerous isolates included in the rotavirus genus are known to possess all these characteristics. Instead, most isolates have been included in the genus on the basis of morphology, the presence of 11 segments of dsRNA, or antigenic cross-reactivity.
Until 1980, all rotaviruses were thought to have common antigens that were detectable by immunofluorescence, complement fixation, or enzyme-linked immunosorbent assays (ELISAs) (107, 353) and to fall into a limited number of species-specific virus serotypes. Recent studies have shown that neither of these early hypotheses is true. Instead, it is now known that (i) many isolates do not share cross-reacting antigens with the rotaviruses originally shown to cause gastroenteritis in the young (39a, 231, 249) , (ii) many (at least six) human serotypes exist (Table 1) , (iii) strains of animal and human origin occur within the same serotype (Table 1) , and (iv) two genome segments encode neutralization antigens, and these segments can segregate (reassort) independently (153, 237) .
These developments have emphasized the need for and importance of developing a serologic classification scheme for rotavirus isolates that allows for the presence of multiple groups of rotaviruses and for the existence of serotypes which cross species. This need has been addressed by a number of investigators (133, 154, 249, 280) , but a uniform classification system remains to be established.
Although no classification system has been officially adopted, rotaviruses are classified serologically first into groups (or serogroups) containing viruses that share crossreacting antigens detectable by serologic tests such as immunofluorescence, ELISA, and immunoelectron microscopy. Six distinct groups (A to F) of viruses have been described (39a, 231, 249) . Group A, B, and C rotaviruses have been found in both humans and animals; group D, E, and F rotaviruses have been found only in animals (39a). Group A rotaviruses have clearly been established as causing severe diarrheal disease in the young, and they may cause disease more frequently in the elderly than previously recognized (155) . Group B rotaviruses include viruses that have been associated with annual epidemics of severe diarrhea primarily in adults in China (56a, 160, 232, 319, 332) . Group C viruses have been found in sporadic cases and outbreaks of diarrhea in piglets and children, but the severity and number of such infections are unclear (39a, 40a, 309, 342b) . The clinical importance of the group B rotaviruses has begun to be studied owing to the recent establishment of rapid diagnostic tests (46, 231, 356) . Available evidence indicates that infections with human group B rotaviruses have not been widespread outside China, but group B infections in animals are more common (40b, 232) . The description of the non-group A rotaviruses is important, and the potential impact of these other groups of viruses to ongoing vaccine programs with the group A rotaviruses must be assessed. Because only one non-group A rotavirus strain has been successfully cultivated (a group C virus [292] ), only limited information is available. Existing data suggest that the group B and C viruses have structural proteins similar to those of the group A viruses reviewed here (39, 46, 92, 103) . Lack of reassortment of genes between viruses in different groups may be a useful criterion for taxonomic differentiation of virus groups. Unless noted otherwise, this review focuses on the group A rotaviruses.
Viruses within a serogroup are classified further into serotypes. Serotypes are defined by plaque reduction or fluorescent-focus reduction neutralization assays by using antisera to purified virus particles prepared in hyperimmunized animals. These assays measure the reactivity of antibody with the two outer capsid proteins (VP4 and VP7), which induce antibodies with neutralizing activity (151, 153, 237) . In most cases the predominant antibody reactivity in hyperimmune serum is against the glycoprotein VP7. The simplest explanation for this is that VP7 makes up a greater percentage of the virion outer capsid of purified particles (see Table 4 ); alternatively, VP7 induces more specific antibodies than VP4 does following hyperimmunization regimens, possibly because VP4 is lost during preparation or storage of virus. The serotypes of viruses, originally defined by reciprocal neutralization assays with hyperimmune antisera, have now been confirmed to represent types of VP7; this was done by using monoclonal antibodies (MAbs) to specific epitopes on VP7 (26, 74, 120, 303, 330, 339, 340, 342) . Previous references to rotavirus serotypes, therefore, really refer to viruses with specific VP7 types. The ability to successfully determine the VP7 type of viruses directly in stools by using MAb-based ELISAs has greatly simplified virus characterization.
In general, reactivities with VP4 are detected when two viruses generate a one-way (but not reciprocal) cross-neutralization with hyperimmune antiserum. The presence of higher proportions of antibody to VP4 in convalescent-phase antisera than in hyperimmune antisera and of a shared VP4 type between viruses with different VP7 types may explain why convalescent-phase antisera distinguish virus serotypes poorly (132) . Support for this hypothesis is provided by recent estimates of protein-specific antibody levels in serum samples of volunteers to whom rotaviruses were administered (22a, 109, 301). Reagents for distinguishing VP4 types are not yet well characterized (45, 179, 304, 327, 328) . Because serologic assays with hyperimmune antisera are poor discriminators of VP4 types and because the production of MAbs to characterize VP4 types has been slow, other approaches have been used to classify types of VP4. Gene 4 segments (which encode VP4) have been compared by hybridization and by nucleic acid sequencing. These com- parisons suggest that at least nine types of VP4 exist (of which four occur in human viruses [ Table 2 ]). Whether VP4 types (distinguished by these nonserologic methods) actually reflect different antigenic types remains to be determined.
Different virus isolates also can be distinguished by nonneutralizing epitopes located on the major polypeptide of the inner shell (VP6). Two such epitopes, now called subgroup antigens, were first described when human viruses were VOL. 53, 1989 differentiated by ELISAs. These reactivities were originally confused with neutralizing epitopes and were thought to be recognizing serotypes, but ultimately these epitopes were shown to be nonneutralizing and to be located on the inner capsid protein VP6 (174) . Viruses can be characterized as possessing one, both, or neither of these epitopes with subgroup-specific (subgroup I or II) MAbs (137, 150, 323) . Other epitopes not yet compared with the subgroup epitopes have also been found on VP6 (189, 190, 261) . Characterization of virus strains by epitopes on this independent antigen can be useful for epidemiologic studies, for monitoring virus transmission, and for identifying natural reassortants.
Other studies of the antigenic properties of rotavirus isolates have shown that group determinants, or common determinants, are found on most (if not all) of the structural proteins of particles (95) . This has been documented by showing that antisera (and some MAbs) specific for individual polypeptides cross-react with virus strains in all serotypes.
A simple and effective classification of any rotavirus strain seems possible by the use of a cryptogram (modified from that originally proposed by Rodger and Holmes [280] ) that conveys the following information: group/species of origin/ place of origin/strain designation/year/subtype antigens (to indicate the independent antigens encoded on different gene segments). The use of a single letter would simplify the notation. For example, the letter P (to denote the proteasesensitive outer capsid protein VP4 that is the hemagglutinin in some strains) and the letter G (to denote the outer capsid glycoprotein VP7) were proposed at the International Congress of Virology, Edmonton, Alberta, 1987 . The VP6 subgroup antigen would be abbreviated SI or S,,, as already accepted in the literature (352) . An example of this scheme applied to the best-characterized rotavirus strain, the simian rotavirus SAl1, is A/SI/S. Africa/SA11/58/G3,P2,S1. In abbreviated form, this strain would be referred to as A/ SI/SA11/G3,P2,51 or A/SA11/G3,P2,S1. This indicates that SAil contains a type 3 VP7, a type 2 VP4, and a subgroup I VP6. Designation of the SAl1 VP4 as a type 2 is used as an arbitrary example. The designation of groups and numbering of subtype antigens (VP4 and VP7 types) must be standardized by an international committee of veterinary and medical researchers to facilitate scientific communication and the development and exchange of standard reagents.
The preparation of polyclonal typing serum to classify the distinct types of VP4 and VP7 (as has been accomplished for the influenza virus H and N subtypes) would certainly represent a major step in simplifying the characterization of both existing and future virus isolates. However, whether such antiserum can be produced and whether classification by VP4 and VP7 is feasible and useful remains to be demonstrated. Possible problems with this approach are that it remains unknown whether infection with a virus with specific P and G types correlates with protection from a second challenge. In addition, certain combinations of VP4 and VP7 may alter the antigenic structure of these individual proteins (56) and some epitopes on VP7 are shared by viruses with different VP7 types (73, 157) . However, if such changes are subtle or detectable only with MAbs, they may not significantly affect the typing with monospecific polyclonal antisera.
VIRION STRUCTURE
The morphologic appearance of rotavirus particles is distinctive. Intact virus particles resemble a wheel, with short spokes and a well-defined rim, when examined by negative-stain electron microscopy (EM). The name rotavirus (from the Latin rota, meaning wheel) was suggested on the basis of this characteristic (106) . Three types of particles (double-shelled, single-shelled, and core) are often observed by EM (Fig. 1) . SAl double-shelled particles are 76.5 nm in diameter, single-shelled particles are 70.5 nm in diameter, and cores are 50 nm in diameter. Single-shelled particles and cores can be produced by chemical disruption of doubleshelled or single-shelled particles, respectively. It is unknown whether the single-shelled or core particles are identical to subviral particles synthesized during virus replication.
Early structural studies of rotavirus particles agreed that these particles possessed icosahedral symmetry, but the ultrastructure of the virus was controversial. For example, the triangulation number (1) , which designates the relationship between the neighboring fivefold axes of the icosahedral surfaces, was initially reported to vary from 3 to 16 (90, 181, 205, 281) . The application of new techniques (which avoided double-sided images produced by negative staining) to the study of rotavirus structure has recently resolved these earlier discrepancies. Roseto et al. (281) studied the structure of single-shelled rotaviruses by using a freeze-drying technique and reported the existence of 132 capsomeres arranged in a skew symmetry with T = 13. They also showed that the outer layer contained small holes that corresponded one-to-one with holes in the inner capsid. This structure was subsequently confirmed for the inner capsid by Ludert et al. (200) , using the same technique and chemically disrupted particles.
The three-dimensional structure of double-and singleshelled rotavirus particles, determined at a 4-nm resolution Po/OSU, Po/SB-lA 8
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The numbering of types of VP4s shown here is arbitrary. These VP4 types have been defined by nucleic acid hybridization and sequence studies (see Table 3 for references). Whether such differences reflect antigenic differences is uncertain.
by using cryoelectron microscopy and image-processing techniques (264) , provides new insights into the virion structure (Fig. 2 ). These studies have unequivocally established a T = 13 1 (levo) icosahedral surface lattice for the two outer layers. A distinctive feature of the virus structure is the presence of 132 large channels spanning both shells and linking the outer surface with the inner core; 120 channels are along the six-coordinated centers and 12 are along the five-coordinated centers.
Three types of channels can be distinguished on the basis of their positions and sizes. The type I channels are those running down the icosahedral fivefold axes, the type II channels are those on the six-coordinated positions surrounding the fivefold axes, and the type III channels are those on the six-coordinated positions around the icosahedral threefold axes. Type III channels are about 14 nm in depth, and they are about 5.5 nm wide at the outer surface of the virus. Going into the particle, these channels constrict and then widen, and their maximum width is close to the surface of the inner-shell proteins. Similar features and dimensions are seen in the other two types of channels, except that type I channels have a narrower (ca. 4.0-nm) opening at the outer surface of the virus. The biological role of these channels is not yet clear, but it is likely that they are involved in importing the metabolites required for RNA transcription and exporting the nascent RNA transcripts for subsequent virus replication processes.
These studies of non-protease-treated virus particles also revealed structural features not seen previously (264) . Sixty spikes, at least 4.5 nm (4.5 to 6.0 nm) in length and each with a knob at its distal end, have been shown to extend from the smooth surface of the outer shell ( Fig. 1 and 2 (Table 3 ). This number, compiled from sequence data of segments from different virus strains, agrees closely with the genome size (18,680 base pairs) determined by EM measurements (279a) .
Hydrodynamic studies of the flexibility or stiffness of isolated rotavirus RNA segments in solution have indicated that these RNA segments cannot be packaged into the rotavirus capsid unless intimate protein-RNA interactions take place. In solution, these RNA molecules possess a "wormlike" or flexible cylinder structure; as an example, RNA segment 1 (3,302 base pairs and a contour length of 928 nm) theoretically cannot be bent into a capsid of 50 nm as a free molecule because the persistence length is 112.5 nm (172) . Therefore, to obtain RNA flexibility, one has to assume that intimate protein-RNA interactions occur in the virion to induce the needed bending and packaging of the dsRNA segments into the virus capsid. The proteins directly responsible for segment packaging remain unclear. The structural proteins present in core particles (VP1, VP2, and VP3) are obvious candidates, but nonstructural proteins may also play a scaffolding role. Deproteinized, purified rotavirus dsRNAs are not infectious, reflecting the fact that virus particles contain their own RNA-dependent RNA polymerase required to transcribe the individual RNA segments into active messenger RNAs (mRNAs) (66) .
Sequences of Rotavirus RNA Segments
The first nucleotide sequences of the rotavirus RNA segments were determined following the development of rapid deoxyribonucleic acid (DNA) sequencing methods and of methods to synthesize dsDNA from templates of either single-stranded viral RNA transcripts or from genomic dsRNA. Once initial sequence information for any RNA segment was obtained, direct dideoxy-chain termination sequencing with reverse transcriptase and oligonucleotide primers with mRNA (or denatured dsRNA segments) often bypassed the need for additional molecular cloning and facilitated the rapid acquisition of comparative sequence information from numerous virus strains. The nucleotide sequences of the 11 RNA segments from different virus strains are known (Table 3) , and the complete nucleotide sequence of one group A rotavirus (SAl) should be established soon. Sequence data and direct measurements of the lengths of rotavirus dsRNA molecules by EM were used to determine the translation, or axial distance, between base pairs in RNA duplexes. The rise per base pair in a helix of dsRNA was found to be 0.28 ± 0.011 nm, indicating that dsRNA contains from 1.16 to 1.17 times more nucleotides per unit length than does dsDNA (332a). The properties of each RNA segment and its encoded polypeptide(s) are described below.
General Primary Structure of Genome Segments
The nucleotide sequence data (Table 3) reveal general features about the structure of each of the 11 genome segments and sequences common to all RNA segments (see Fig. 3 to 8) . Each RNA segment starts with a 5' guanidine followed by a set of conserved sequences that are part of the 5' noncoding sequences; an open reading frame coding for the protein product follows, and another set of noncoding sequences, which contains a different subset of conserved 3'-terminal sequences and ends with a 3'-terminal cytidine, is found after the stop codon. The 5'-terminal consensus sequence 5'-GGC(AIU)(AIU)U(AIU)A(AIU)(AIU) is found only once (in segment 4, base pairs 2166 to 2177) in a position other than at the termini of the other known sequences. The 3'-terminal consensus sequence is U(GIU)(UIG)(GIU)(AI G)CC-3'. The complementary sequence of the 3'-terminal consensus sequence (UGUGACC-3') is also found in segment 5 (positions 1513 to 1519). The lengths of the 3' and 5' noncoding sequences vary for different genes. However, these lengths are conserved among strains for a given gene, with the exception of the 3' end of segment 7 (134 bases for SAl and 112 bases for bovine UK viruses) and segment 10 (from 182 to 186 bases for five different virus strains). There is no preferential use of stop codons, and a polyadenylation signal is not found at the 3' end of the genes. Most of the sequenced segments (except gene 11) possess only one long open reading frame. The first initiation codon (in all genes except 7, 9, and 11) is a strong initiation codon based on Kozak's rules (185, 186) . For genes 7 and 9, the second in-phase AUG is the favored initiation sequence. For gene 7, it is unknown which AUG is used. Some evidence (see below) indicates that gene 9 is a bicistronic gene (49) . Gene 11 contains a second in-frame open reading frame and also an out-of-frame open reading frame that are conserved in all of the segment 11 sequences found to date. The initiation codon for the second out-of-frame open reading frame is a favorable one, but it is not known whether this second reading frame is used.
All of the rotavirus gene sequences are A+T rich (58 to 67%), and the codon usage is biased against CGN and NCC codons, as in many eucaryotic and other viral genes (260) . The RNA segments are base paired end-to-end, and the plus-sense strand of the genomic dsRNA contains the capped 5' sequence m7GpppG(m)GPy (161, 218) . Similar features of the RNA termini (capped structures and 5' and 3' conserved sequences) are found in the primary structures of the genome segments of other viruses (e.g., reovirus, cytoplasmic polyhedrosis virus, and orbivirus) in the family Reoviridae (116, 187, 222) , and 5' and 3' conserved terminal sequences are also found in other virus families with segmented genomes (Orthomyxoviridae, Arenaviridae, and Bunyaviridae). Therefore, these terminal sequences are thought to contain signals important for genome transcription, replication, and possibly assembly of the viral genome segments.
Secondary Structure of Rotavirus Genome Segments or
Viral Transcripts Potential regions of intramolecular base-paired (secondary) structures of the plus strand involving terminal regions have been described for gene segments 4, 10, and 11 (162, 171, 244) . These structures are hypothesized to influence gene expression during either RNA replication or translation, and they have caused difficulties in obtaining full-length complementary DNAs (cDNAs). Examination of terminal sequences of each known gene sequence for direct and inverted repeats shows that several segment ends contain regions with statistically significant similarities. These regions could represent gene duplication and aberrant transcription events of both strands of the genome. However, the distribution of these patterns does not lead to a selective association process that could explain gene reassortment, a finding also previously described for reoviruses (7) . Thus, it can be hypothesized that the reassortment of the 11 segments probably involves RNA-protein interactions.
VOL. 53, 1989 416 ESTES AND COHEN Table 4 ), and sequences of the cognate gene in other strains are listed on the basis of homology with the SAII gene. For some strains, this represents a different RNA segment based on electrophoretic migration on polyacrylamide gels. For example, the SAil genome segment 8, the bovine UK genome segment 7, and the rhesus rotavirus genome segment 9 encode NS35, whereas SAII genome segment 9, UK genome segment 8, and RRV genome segment 7 encode VP7 (80, 123, 124, 208, 217) . Such shifts are most common for genome segments 7, 8, and 9. The order of migration of segments 10 and 11 is also changed between viruses with long and short RNA patterns. The size of each segment is given only for the first virus listed and may differ for the same segment in other virus strains. Segment size differences have been reported for genome segments 4, 7, 10, and 11, and these differences may be due to genetic drift, rearrangements of sequences within a segment, or sequencing errors (see text).
viruses which each have a type 3 VP7 suggests that there are species-specific sequences in this gene (234a), as well as serotype-specific regions (see below and Fig. 6 ). The identification of species-specific, unique amino acid sequences in this gene suggests that the VP7 gene is involved in interspecies reassortment with low frequency in nature (234a). The biologic properties and antigenic composition of particles may be altered by such genomic evolution, but this is only beginning to be understood. Interesting recent results indicate that the antigenic composition of particles may be influenced by the interactions of specific combinations of the two outer capsid proteins, by trypsin treatment of particles, or by oligosaccharide addition at different sites on the outer capsid glycoprotein (47, 56, 72, 203, 302) .
Genome Analysis for Virus Detection Rotaviruses are the only mammalian agents known to contain 11 segments of dsRNA. In most cases, the genome of the group A viruses is composed of four high-molecularweight dsRNA segments (segments 1 to 4), five middle-sized segments (segments 5 to 9) including a distinctive triplet of segments (segments 7 to 9), and two smaller segments (segments 10 and 11). Analysis of the genome pattern of virus specimens is relatively easy and rapid; therefore, this technique has become a useful and popular procedure for virus detection and for molecular epidemiology studies (see references 53 and 96 for reviews).
Although in most cases the basic pattern (158, 215, 250, 256, 325) . Viruses with such genome rearrangements have been isolated from immunodeficient, chronically infected children (250) , asymptomatically infected immunocompetent children (24) , and animals (calves [256] , pigs [23] , or rabbits [325, 335] ). They have also been obtained after serial in vitro passage of a tissueculture-adapted bovine rotavirus at high multiplicity of infection (158) . Isolates with rearrangements in segments 5, 6, 8, 10, and 11 (27, 158, 159, 215, 250, 256, 325) have been characterized, with the greatest number having rearrangements in segment 11. In retrospect, it is possible that short and super-short RNA patterns reported for human viruses reflect rearrangements in genome segment 11 (81) . In fact, determination of gene 11 sequences from these strains has shown that they contain insertions of A+T rich 3' noncoding regions which are not significantly homologous to each other, to other parts of gene 11, or One proposed mechanism for these rearrangements that is compatible with the available data is that at various stages of initial transcription, the virion-associated RNA polymerase falls back or jumps to a second site on its template to reiterate part of it in the transcript (124a, 129a, 159) . Such copy choice mechanisms have been documented to explain production of deletion-defective particles of vesicular stomatitis virus and coronavirus recombinants (192a, 204a (81, 207, 208, 217, 307) and by analyses VOL. 53, 1989 418 ESTES AND COHEN of reassortant viruses (123, 168, 194, (237) (238) (239) 341 (183, 184, 294 ) (see below), and these provide explanations for other discrepancies.
The nomenclature of the viral proteins has recently been changed (194) . We originally proposed the designation of the SAl structural proteins as viral protein (VP) followed by a number, with VP1 being the highest-molecular-weight protein, and proteins generated by cleavage of a larger precursor were indicated by an asterisk (VP4 is cleaved to produce VP5* and VP8* [11, 97] ). Our initial studies failed to identify a protein product from gene segment 3, and the protein product of gene segment 4 was called VP3 (208) . When recent studies showed that the protein of gene segment 3 is a structural protein located in the inner core, for consistency we called the gene 3 product VP3 and renamed the gene 4 product VP4 (194) . This new nomenclature is used throughout this review and will be used in all our future publications, but it should be realized that much of the literature on "VP3" up to and including 1988 refers to the gene 4 product.
Our naming the gene 3 protein VP3 brings into agreement our nomenclature system for SAl with that for the UK virus for the products of genes 1 to 4 as designated by McCrae and McCorquodale (217) and for several human rotavirus strains (294) . Our finding that the four largest RNA segments code for structural proteins confirms the earlier reports of others (149, 307) and also requires changes in another nomenclature system, in which the nonstructural proteins were called NCVP1 to NCVP5 and the gene 3 product was called NCVP1 (11, 33 One unusual property of VP1 is that it often fails to react in immunoprecipitations or in immunoblots with many hyperimmune antisera made to purified virus particles (88) or with serum from naturally or experimentally infected children or animals (61, 69, 240) . Other serum samples can precipitate VP1 (324; J. Cohen, unpublished observation), and the successful production of a VP1-reactive antiserum (by immunoprecipitation, immunofluorescence, and immunoblots) by immunizing animals with VP1 synthesized with a baculovirus expression system indicates that this protein is antigenic and immunogenic (66a). The different capacity of sera to react with VP1 after natural infection or parenteral immunization may be explained by the degree to which VP1 is accessible to the immune system. VP1 was partially accessible to iodination in single-shelled but not doubleshelled particles (236) . This suggests that either VP1 is exposed on single-shelled particles or the channels that penetrate into the inner core of particles are large enough for iodination reactions to occur inside the particles. Examination of whether antibody to VP1 reacts with single-shelled particles may help to answer this question. VP2. VP2, encoded by genome segment 2, is the most abundant structural protein found in core particles (25, 194) and is the third most abundant protein in double-shelled particles. Lactoperoxidase-catalyzed iodination experiments suggest that VP2 is partially exposed on single-shelled particles (236) , and this idea is supported by the demonstration that antibodies to VP2 are able to react by ELISA with single-shelled particles bound to plates (331) . However, since direct binding of particles to plates can induce conformational changes in particles (45, 121) , immunoelectron microscopic examination of whether these antibodies directly bind to particles would help to interpret these results. VP2 is highly immunogenic, and serum antibodies to this protein are a good indicator of prior infection (69, 324) .
VP2 is the only structural protein shown to possess nucleic acid (dsRNA, ssRNA, and dsDNA)-binding activity when evaluated by an RNA overlay-protein blot assay (37). Table 3 for references. b Number of 5' noncoding sequences is up to the first AUG; number of 3' noncoding sequences does not include the termination codon. 'Determined by biochemical and genetic approaches (see text). The size (in thousands) of the primary translation product is given for the nonstructural (NS) proteins.
d Molecular weights are calculated from the deduced amino acid sequences from nucleotide sequence data. The molecular weights are calculated from the largest potential open reading frame.
e Adapted from Liu et al. (194) . These estimates are not totally consistent with estimates of the numbers of molecules of VP4, VP6, and VP7 (120, 780, and 780 molecules, respectively) made from structural analyses of particles (264; Prasad et al., submitted for publication).
f From Gombold and Ramig (123, 124) . NA indicates that none was assigned. g See text for references.
h There are two trypsin cleavage sites in SAl 4fM VP4 at amino acid 241 and 247. The indicated mature products are those based on the use of only the preferred second cleavage site (195, 196) . i Mature cleaved VP7 contains 276 amino acids.
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VP2 binds ssRNA in preference to dsRNA, but the binding is not sequence specific. Analysis of the sequence of VP2 shows that this protein contains leucines at every seventh residue, starting at amino acids 536 and 665. Such a periodic array of leucines (leucine zipper [192] ) is hypothesized to represent a part of a protein that molds it to interact with a target site on DNA (and probably on dsRNA) ( Fig. 3) (188) . VP2 may be a nucleocapsid protein that is bound tightly to the RNA segments. The apparent molecular weight (of 94,000) of VP2 calculated from its mobility on sodium dodecyl sulfate-polyacrylamide gel electrophoresis differs from the molecular weight (of 102,431) deduced from the nucleotide sequence. This may result from the high percentage of predicted alpha helix in this protein. VP2 has been found to be myristilated, and although the functional significance of this is unknown, such modification in other viral systems has been found on scaffolding proteins important for the formation of virus particles (59) . Epitopes on VP2 that cosegregate with subgroup specificity of VP6 also have been reported (331) , but other biologic properties of VP2 are not yet known. MAbs to VP2 should be useful to further probe the function of this protein in the assembly of rotavirus particles or in RNA replication.
VP3. VP3, encoded by genome segment 3, is a minor structural protein that may comigrate with the outer capsid protein VP4 in many gel systems (194) . In early studies, this gene product was reported to be a structural protein (307), a nonstructural protein (11) , or a structural protein that was translated poorly in vitro and was synthesized and processed rapidly (217) . These early studies all approached analysis of the genome segment 3 protein by comparing the proteins synthesized in infected cells with those translated in cell-free systems. A reevaluation of this question for SAil involving the use of reassortant viruses and new methods of electrophoresis of the proteins on polyacrylamide gels confirmed that four proteins are located in single-shelled particles and three proteins are located in core particles (194) , as shown earlier by others (25, 307) . The poor cell-free translation of this gene product has been confirmed and remains unexplained. The sequence of gene 3 indicates that this segment codes for a protein of 835 amino acids with a predicted molecular weight of 98,120 (M. Liu and M. K. Estes, Nucleic Acids Res., in press). Analysis of the deduced amino acid sequence indicates that this is a basic protein that contains multiple repeats of amino acids. Homology with other RNA polymerases from other viruses also suggests that this protein is involved in RNA replication (Liu and Estes, in press).
VP6. VP6 is encoded by genome segment 6 and is the major structural protein in virus particles located on the outer surface of single-shelled particles. Biochemical characterization of VP6 removed from particles revealed that it is a trimer (129, 288) , and three-dimensional structural studies of single-shelled particles have shown trimers to be present on the surface of these particles (264) . Trimerization and formation of tubules is an intrinsic property of this protein, since VP6 synthesized in the absence of other viral proteins forms such structures (94) . VP6 removed from particles will also form tubules and viruslike particles at low pH, but whether other proteins play a role in these reactions remains unclear (273) . These results and biochemical data showing that VP6 is removed from inner-core particles prepared by treating single-shelled particles with chaotropic agents (25, 194, 293) counter the suggestion (based on iodination results with single-shelled particles) that VP6 is more internal than VP2 in particles (236) . Alternative interpretations of these iodination results are that (i) the tyrosine residues required for iodination are not accessible in trimeric VP6; (ii) the channels leading into the inner particle are large enough to permit the iodination reactants (lactoperoxidase) to penetrate the particles and therefore label VP2; and (iii) VP2, which is a core protein that may bind to the RNA segments, Biochemical and immunologic approaches have been used to examine whether VP6 performs specific biologic functions during virus replication. Removal of VP6 from single-shelled particles results in a loss of transcriptase activity of particles. Readdition of VP6 to stripped single-shelled particles restores transcriptional activity, and addition of excess VP6 to stripped single-shelled particles inhibits transcription (25, 293) . These experiments indicate that VP6 is required for polymerase activity, but they do not directly prove that VP6 itself is involved in transcription. VP6 may merely be important as a structural component of particles to maintain the proper conformation or organization of the viral core structure or transcriptional complex composed of one or more of the core proteins. VP6 is myristilated, and this modification may be important for formation of virus particles or for targeting single-shelled particles to the ER membrane for budding (59) (see below).
VP6 is both highly immunogenic and antigenic, and it is the most frequently targeted protein in diagnostic assays to detect virus particles. VP6 contains common (cross-reactive) epitopes shared by other group A viruses, and it can contain zero, one, or several forms of an antigen called the subgroup antigen (137, 168, 174, 190, 323) . Whether VP6 plays a role in inducing protective immunity remains unclear.
Some MAbs to VP6 have been reported to possess low levels of activity that neutralizes virus infectivity when assayed in vitro (288) . In addition, a synthetic peptide corresponding to aa 40 to 60 of VP6 has been reported to induce protective immunity in a mouse model of passive protection (111) . These results contrast with most studies, which have failed to detect neutralization with anti-VP6 MAbs (119, 139, 150, 282, 305, 312) or with polyclonal monospecific serum raised to VP6 synthesized with a baculovirus expression system (94) . It is possible that neutralization activity observed with VP6 antiserum is not specific but is caused by nonspecific trapping of infectious doubleshelled particles owing to the aggregation of single-shelled particles present in most virus preparations. Neutralization activity detected with polyclonal monospecific serum made to gel-purified VP6 (178, 287) is difficult to interpret because of questions of the specificity of these sera. Contamination of the VP6 from gels with small amounts of the closely migrating VP7 can result in a neutralizing antiserum as a result of antibodies to VP7 (M. K. Estes, unpublished data).
The subgroup epitopes on VP6 detected by MAbs (137) have been used as an epidemiologic tool to monitor the antigenic properties of different virus strains. To date, attempts to map the location of the subgroup epitopes by using biochemical or molecular techniques have met with limited success because many of these epitopes are conformational and appear to be located on the trimeric but not monomeric structures (128) . Analysis of VP6 with a panel of MAbs has indicated that VP6 possesses at least five nonoverlapping epitopes (261) . Unfortunately, none of these MAbs or others to VP6 (128, 189, 190) have been directly compared with the original subgrouping MAbs to permit comparisons of results. Use of a rapid and simple method to map epitopes will facilitate such needed comparisons (45) .
A rotavirus strain that was isolated from horses (FI-14) and that possesses both subgroup I and II epitopes has been identified (150) . Sequence analysis of gene 6 of this virus suggested that two VP6 proteins may be produced from two different initiation codons (128) . This study also determined the sequence of VP6 from several new virus strains and confirmed regions of sequence divergence recognized previously (36, 68, 99, 148) ; unfortunately, it did not shed further light on the map sites of the subgroup or common epitopes on VP6 (128) . Comparison of the sequences of different virus strains has identified one region of fairly high sequence variation (Fig. 3 ), but no function has yet been mapped to this or other sites. Additional virus strains which lack subgroup I and II epitopes have been described (323) , and sequence analyses of these strains may help define regions on VP6 which react with the subgroup MAbs. Use of MAbs which react with either the monomeric or trimeric form of VP6 should help us to understand the process of trimerization and the role of VP6 in the viral morphogenetic process (14; L. Svensson, personal communication).
Outer Capsid Proteins VP4. VP4 is the protein product of genome segment 4, and it is a nonglycosylated outer capsid protein and a hemagglutinin in many virus strains (167, 208) . It is responsible for a number of biologically important functions. In the presence of trypsin, VP4 is cleaved into VP5* (molecular weight approximately 60,000) and VP8* (molecular weight approximately 28,000), and this cleavage results in enhancement of viral infectivity (91, 97) . Cleavage of VP4 has been shown to enhance penetration (but not binding) of the virus into cells (64, 113, 169) . VP4 is also associated with restriction of the growth of certain rotavirus strains in tissue culture cells (137) and in mice (238) and with protease-enhanced plaque formation (167) . Antibodies directed at VP4 neutralize rotavirus in vitro (45, 71, 137, 139a, 153, 179, 329) and passively protect mice against heterologous rotavirus challenge in vivo (210, 238) . Further studies have suggested that VP4 induces protective immunity in animals (239) and is immunogenic in children and animals (69, 301, 324 (204, 327) . Direct amino acid sequence analysis of VP4, VP5*, and VP8* of a strain called SAl 4fM determined the site of trypsin cleavage (196) . Both VP4 and VP8* had blocked NH2 termini, and the VP5* of SAl 4fM was found to be composed of two polypeptides with slightly different amino acid sequences at their NH2 termini. Comparison of these data with the deduced amino acid sequence of SAl 4fM VP4 identified two trypsin cleavage sites (arginine 241 and arginine 247), with the latter position being the preferred cleavage site (196) . Subsequent nucleotide sequencing across this region of gene 4 in other strains revealed that the two trypsin cleavage sites at arginines are conserved in every rotavirus VP4 sequence analyzed (Fig. 5 ) (197 arginine is found just before the 3'-proximal arginine site (aa 246 in human strains, aa 247 in animal strains [126, 196] ). It is unknown whether these sequence differences at the trypsin cleavage site affect the biologic properties of different virus strains, but the additional trypsin cleavage site in some human viruses has been suggested to be correlated with virus virulence, because viruses with this extra site were originally isolated from children with symptomatic infections (Fig. 5 , lines RV-5, WA, P, and VA70) (126, 130) . Ninety-one amino acids on VP4 are conserved among strains from children with asymptomatic infections (Fig. 5 , lines M37 and ST3), whereas a different amino acid is conserved at each of these sites among virulent rotaviruses (126) . In addition, three of these amino acids are located within the 6-aa connecting peptide between the two cleavage products of VP4 (126) . Some or all of the 91 differences in VP4 amino acids between viruses from asymptomatic and symptomatic children have been postulated to be responsible for the difference in virulence of these two groups of human rotaviruses, because none of the other 10 rotavirus gene segments are conserved among asymptomatic or virulent strains (108) . The significance of these findings is unclear, because far fewer amino acids are conserved if one compares the conserved sequences in asymptomatic strains with those in virulent animal strains (Fig. 5) and there is no proof that the strains from asymptomatic newborns are really avirulent. Other studies have suggested that host (rather than viral) factors may cause asymptomatic disease in newborns, because virus strains that cause disease in older children often cause asymptomatic infections in newborns (338, 344) .
The mechanism of cleavage activation of infectivity is not clear from the sequence analyses alone. It is thought that cleavage of VP4 activates an early step of replication which may be triggered by one or both of the terminal regions generated by the cleavage or by a possible conformational change in cleaved VP4 molecules. Trypsin activation of orthomyxoviruses and paramyxoviruses generates a highly conserved apolar amino terminus, and the infectivity of these activated viruses can be blocked by oligopeptides that mimic this sequence (274, 275) . The new terminus generated by cleavage in the rotavirus VP4 is not hydrophobic; instead, it contains many polar amino acids (some of which might be charged at neutral pH). Therefore, the mechanism of activation of rotavirus infectivity is apparently different from that postulated for other viruses. Since rotavirus infectivity has been shown to be enhanced by trypsin, elastase, and an uncharacterized acid-stable enzyme in pancreatin (but not by chymotrypsin [132] ), further examination of the sites of natural cleavage may be useful to understand activation. It also remains unknown whether cleavage at both sites results in removal of the small intervening peptide and whether the minor and major cleavage sites shown to be used for SAl 4fM are used identically for other virus strains.
Studies are just beginning to determine whether the cleavage region (and the intervening peptide) possesses any functions. The region (aa 228 to 241) adjacent to the cleavage region has been shown to induce neutralizing antibodies by immunization of rabbits with a synthetic peptide to this region. The antipeptide serum showed strain-specific lowlevel neutralizing activity, and it bound to virus particles in ELISAs and aggregated particles by immunoelectron microscopy (317) . Neutralization titers were increased (from 800 to 3,200) following assay of trypsin-treated virus-antipeptide serum complexes. Trypsin treatment of virus particles also has been shown to result in loss of reactivity of the virus with a nonneutralizing antibody to the glycoprotein VP7 (72 (64, 113, 169) and acidification of endosomes is not important for virus entry (114, 176, 201 (126, 170, 171, 204, 235 ). An additional cysteine is present at aa 266 in the human M37 strain (126) and at aa 203 in SAl1, SAl 4fM, bovine 486, and RRV. It has been proposed that the trypsin cleavage site is kept accessible through disulfide bonds at cysteines 203 and 216 in VP8* and at cysteines 318 and 380 in VP5*; lack of Cys-203 was suggested to explain the poor growth of human rotavirus strains in cell culture (204) . This seems unlikely since the bovine UK virus, which grows well in vitro, has a serine at aa 203 (171) . However, the regions flanking the trypsin cleavage sites (aa 224 to 235 and 257 to 271) are relatively highly conserved in all strains, and these could serve to hold the cleavage sites in the proper conformation for cleavage.
Sequencing of escape mutants selected with neutralizing MAbs has identified amino acids involved in homologous and heterologous neutralization (204, 327) . VP8* contains predominantly type-specific sites, and five such sites (Fig. 4 , sites 1 to 5) have been localized in VP8* (204, 304) . Crossreactive MAbs from two different laboratories have been located on VP5* clustered in a relatively limited area at aa 306, 388, 393, 434, and 440 (204, 327) . These positions are based on the numbering for the animal rotavirus strains (i.e., aa 306 would be 305 in the human virus VP4). One MAb (site 6) that neutralizes viruses in serotypes 3, 5, and 6 (based on VP7 reactivities) is located at aa 393 in the middle of the conserved hydrophobic region and the putative fusion region. Other cross-reactive MAbs (epitope II) for human viruses cause changes at aa 392 and 439 (393 and 440 of animal strains), suggesting that this site is conformational (327) . Another cross-reactive site (epitope I) is sequential ( linear) on the basis of reactivity with a synthetic peptide from aa 296 to 313, and aa 305 of the human VP4 is apparently critical for this epitope (327) . The cross-reactive epitope I site and an epitope III site (at aa 433) have been identified only by one set of MAbs (327, 328) . None of these MAb-identified neutralization regions corresponds to the cleavage region shown to be immunogenic by injection of synthetic peptides from the cleavage site (317) (see above). This suggests that variability exists in the immunogenicity of distinct regions of VP4, and the relative immunogenicity of these epitopes remains to be clarified.
Comparisons of the segment 4 sequences of viruses in different serotypes to look for regions of diversity show that homologies are not evenly distributed across VP4 (Fig. 5) . The most distinct sequence variation is seen between aa 71 and 204 in VP8* (Fig. 5) . It is tempting to speculate that VP8* is externally exposed on the virus particle, since VP8* contains the locations of greatest sequence diversity and of binding of the strain-specific MAbs (whereas cross-reactive sites have been mapped to VP5*) and since VP8* is predicted to be globular. If readily exposed, the sequence diversity in VP8* could easily arise by immune selection. No function or neutralization epitopes have yet been mapped to this variable domain. A second region of sequence variations is found between aa 578 and 608.
Attempts to locate other functional domains on VP4 have not yet been successful. Genetic analyses show that VP4 is the hemagglutinin, and hemagglutination activity has been demonstrated with VP4 molecules expressed by baculovirus recombinants (202; S. E. Crawford and M. K. Estes, unpublished data). The site on VP4 that binds to erythrocytes remains unknown, but it may involve several regions of VP4 because MAbs to both VP5* and VP8* can inhibit hemagglutination (45, 139a, 179, 304) . However, some of these MAbs may inhibit hemagglutination by steric hindrance. Site-specific mutagenesis and high-resolution structural studies of particles or of individual proteins are needed to answer these questions.
VP7. VP7 is the second most abundant capsid protein and is encoded by genome segment 9 of SAl1, genome segment 8 of the UK bovine virus, and genome segment 7 of rhesus rotavirus. This outer capsid glycoprotein is highly immunogenic and induces neutralizing antibodies. Recognition that this neutralization antigen is a structural glycoprotein stimulated numerous studies of the structure, biosynthesis, and functions of VP7. Biochemical analyses rapidly determined that (i) VP7 is a glycoprotein that contains only N-linked high-mannose oligosaccharide residues, which are added cotranslationally as this protein is inserted into the membrane of the ER, and (ii) VP7 is an integral membrane protein with a luminal orientation whose oligosaccharides are modified by trimming which occurs only in the ER (89, 165 ; see the section on eucaryotic protein targeting and oligosaccharide processing).
The nucleotide sequence of VP7 from virus strains in six human serotypes and two animal serotypes and the deduced protein amino acid sequence reveal several interesting and possibly biologically relevant features of this gene and its deduced protein ( Fig. 6 and 7 
: 
Comparisons of the deduced amino acid sequences of VP4. The sequences of six strains of human rotaviruses and four strains of animal rotaviruses are shown with cysteine (X) and proline (V) residues conserved in all strains being indicated. The arrows highlight the trypsin cleavage site(s) known to be used in SAil at aa 241 and 247 and another potential site at aa 231. The additional potential trypsin cleavage site found in some human rotavirus strains is boxed, and dots (0) show the amino acid missing in human strains at residue 136 of the animal strains. The region of high sequence variation in VP8* (aa 71 to 204) and the relatively conserved hydrophobic region in VP5* (aa 385 to 404) which contains the putative fusion region are highlighted by dashed boxes. The sites of amino acid changes of neutralization escape mutants are marked by a bar. Altered sites found in neutralization escape mutants with MAbs that react with viruses in more than one serotype are marked by an X; X indicates site of amino acid changes of neutralization escape mutants, as well as an altered site that reacts with viruses in more than one serotype. The sequences shown are for SA1l (235) , SAil 4fM (195, 196) , bovine 486 (262), rhesus RRV M18006 (204) , human RV-5 (170), and human M37, ST3, WA, P, and VA70 (126) . The human viruses RV-5, WA, P, and VA70 were isolated from children with symptomatic infections; the human viruses M37 and ST3 were isolated from children with asymptomatic infections (126 codon, found 42 nucleotides downstream from the second hydrophobic domain, is not present in all strains. The simian rotavirus SAIl strain contains one potential N-linked glycosylation site at aa 69 which is utilized; this site is found in all other viruses, including the bovine UK strain, but it is missing in the bovine NCDV and RF strains. These bovine and other strains contain other potential glycosylation sites at aa 146, 238, and 318 (54, 122, 135, 142) , confirming biochemical studies indicating that some strains contain two glycosylation sites in VP7 (183, 294) . The location of the second site of glycosylation is not known for any strain. A region (aa 133 to 146) that is well conserved in rotavirus strains examined so far (except ST3) shares similarities with Ca2'-binding sites of other proteins. This region is between two predicted alpha helices and contains six amino acids with oxygen atoms on their side chains that may coordinate the interaction with calcium. The sequence divergence in this putative region for VP7 of the human ST3 strain suggests that differences in the calcium-binding capacity of distinct strains may exist. The presence of this Ca2+-binding site may explain why VP7 can be removed from double-shelled particles by chelation of calcium ions (67) . Although no direct proof of calcium binding to VP7 has yet been shown, calcium has been shown to bind to double-shelled and not to single-shelled particles (299) .
The biosynthesis of VP7 from SAl has been studied in some detail. Because the two in-frame initiation codons are conserved in all rotavirus strains examined to date, this gene is potentially bicistronic. Furthermore, since translation from such multiple in-phase initiation codons has biologic significance in other viral systems (186, 234, 251) , it is of interest to know whether the second in-phase initiation codon is used. Two bands of VP7 are detectable when the proteins in preparations of purified SAl are analyzed on polyacrylamide gels (49, 316) , and similar bands also were noted in infected cells by others (82) . On the basis of biochemical studies and cell-free translation of VP7 in wheat germ lysates, it was suggested that these bands may result from the initiation of translation of two primary gene products from the first two in-phase initiation codons, with subsequent distinctive processing of these proteins (49) . These studies also hypothesized that the final protein products would have different amino termini owing to different processing of signal peptides of the two primary products (49) .
Studies designed to determine the site of cleavage of the signal peptide in VP7 initially were unsuccessful because viral VP7 has a blocked amino terminus (10, 316) . However, reevaluation of this question by using gene constructs containing altered initiation codons showed that proteins translated from either initiation codon are processed in vitro in rabbit reticulocyte lysates to yield products identical in size (316) . Therefore, the primary translation products appear to be cleaved at the same site. Amino-terminal sequence analysis identified Gln-51 as the amino-terminal residue of at least some molecules of VP7 from purified virus. Gln-51 is conserved in all strains, and pyroglutamic acid has been identified as the blocking group (316) . Since these studies indicate that the processed products translated from either the first or second AUG are the same, it would seem that the first AUG is not needed to produce VP7. This raises the question of why this first initiation codon is conserved in all VP7 genes. Possibly this codon is used in vivo to produce low levels of a protein with a subtly different property or the conserved RNA sequences in that region have a specific function. Further studies are required to resolve this issue.
Experiments with bovine rotavirus and human rotaviruses indicate that VP7 is the cell attachment protein (113, 213, 287) . Initial studies showed that a polyclonal monospecific antibody, made to native VP7 purified by isoelectric focusing in glycerol gradients, blocked the adsorption of radiolabeled virus to MA104 cells (213) . Later studies reported that soluble VP7 in infected cells binds to monolayers of intact target cells. Binding of soluble VP7 is blocked by virus particles, and binding of radiolabeled virus is blocked by anti-VP7 (but not anti-VP4) MAbs (113, 287) . Adsorption of rotavirus to tissue culture cells has also been shown to be independent of trypsin treatment of virions normally needed for virus infectivity (64, 113) .
In studies to identify and characterize the domain on VP7 (Fig. 7) (54, 135, 206) . Other investigators also used the same VP7 peptide (aa 275 to 295) from SAl virus to immunize rabbits (142) . The SAl peptide was immunogenic, and antiserum produced to it reacted with denatured VP7 on immunoblots, but this serum failed to bind to or neutralize virus (142 One possible explanation for the conflicting results (described above) and a major problem in evaluating the immunogenicity of peptides or expressed rotavirus proteins (see below) is the difficulty of obtaining seronegative animals for immunization. Rotaviruses are ubiquitous, and many investigators have shown that sera from "normal" animals (including prebleeds and negative controls) contain antibodies to rotavirus proteins (241, 286, 318) . Therefore, all animals must be carefully screened to prove that they are seronegative, and conclusions from studies of animals with preexisting antibodies must be interpreted carefully, because biologic activities in sera from primed and boosted animals may not accurately reflect the immunogenicity of the inoculum.
Conformation maintained by disulfide bonds has been shown to be important in maintaining neutralizing epitopes on VP7. This was first suggested by the inability to produce hyperimmune antiserum with neutralizing activity against VP7 purified from denaturing polyacrylamide gels (20, 95, 287 Fig. 6 and 7) . Six regions are evident on the basis of the divergence of nucleic acid sequences between viruses with different serotypes (Fig. 7) . However, only five of these are apparently present in mature VP7, and only three of these regions (A, B, and C), located at aa 87 to 101, 142 to 152, and 208 to 221, respectively, have been confirmed to be involved in neutralization, based on mapping the sequence changes in neutralization escape mutants (84, 203, 326) . The mapping of such mutations (in escape mutants made with neutralizing MAbs that are strain specific or that cross-react between viruses in different serotypes) also has allowed locations of cross-reactive (in region A) and strain-specific (in regions A and C) epitopes to be determined (Fig. 7) (203, 326) . These results, together with competition results of the neutralizing MAbs, indicate that the three-dimensional folding of the native protein brings regions A and C in close proximity (84) . Region C appears to be the most important, since a mutant containing an amino acid substitution within this region was found to have a markedly increased resistance to hyperimmune antisera (84) . On the basis of these results, region C has been suggested to be an immunodominant antigenic site.
The study of viruses with different numbers of glycosylation sites (from zero to two) on VP7 is beginning to show that glycosylation can modulate the biologic and antigenic properties of VP7. The observation that an SAil variant with a nonglycosylated VP7 is infectious and possesses the biologic properties of hemagglutination and serotype specificity indicates that glycosylation is not essential for these functions (254; Estes, unpublished). Selection and characterization of neutralization escape mutants of this nonglycosylated variant of SAil found that some mutants possessed an amino acid substitution at residue 238 of VP7, whereas mutants of wild-type SAil (selected with the same antibody) contained an amino acid substitution at residue 211 (in the C antigenic region). In both cases, the mutations produced new potential glycosylation sites, and these were found to be utilized. These mutations led to gross antigenic changes, which were found to be reversible upon removal of the attached carbohydrate (47 (203) .
Identification of the location of specific glycosylation sites on VP7 in strains with several potential sites may help interpret existing and future studies, including anticipated high-resolution structural studies of VP7. It will be particularly interesting to see whether the potential glycosylation site at aa 318 is used, since this carboxy-terminal region of VP7 should be exposed, based on the reactivity of virus particles with an antiserum made to the carboxy-terminal 8 aa of SAil VP7 (318) 
-~~S--VD- ---- (294) , and only the faster-migrating 35K band possessed cell-binding activity (113 A significant reduction in outer-shell assembly has been reported when bovine and human rotavirus strains (which contain two sites of glycosylation of VP7) are grown in the presence of tunicamycin (285, 322) . This contrasts with the observation that double-shelled SAl is made under similar conditions (254) . The outer capsid of human rotaviruses also is easily removed during purification (329) . These results may indicate that assembly or stability of the outer capsid of viruses with more than one carbohydrate moiety may be more complex than for viruses which contain no glycosylation sites or only one glycosylation site in VP7. Continued studies with a variant of SAl (which apparently possesses a very stable outer capsid and a VP4 with distinct properties) may help clarify how interactions between VP4 and VP7 molecules can influence the biologic and antigenic properties of both outer capsid proteins (44, 56) .
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Many MAbs and polyclonal antibodies to VP7 possess hemagglutination inhibition activity. This activity is thought to be due to steric hindrance because VP4, and not VP7, is the hemagglutinin. This also suggests that VP4 and VP7 interact closely, and it seems likely that such interactions will ultimately be shown to influence many more biologic properties of these viruses than are currently recognized.
Nonstructural Proteins
Our current knowledge of the functions of the nonstructural proteins is generally less extensive than that of the capsid proteins. However, sequence data have begun to yield some information on general protein structure and possible clues about function (Fig. 8) . Ongoing studies of expressed nonstructural proteins are expected to quickly provide more specific information on the roles of these proteins in the replication cycle.
NS53. NS53 is a nonstructural protein encoded by SAl1 genome segment 5. This protein has been found in infected cells but not in virus particles by most (11, 88, 149) but not all (217) investigators. The kinetics of polypeptide synthesis in rotavirus-infected cells show that NS53 is made and is detectable predominantly at early times after infection (88, 236) . The synthesis of this protein is apparently controlled, because in infected cells the levels of NS53 produced are low relative to those of the other viral proteins, whereas in cell-free systems, NS53 is synthesized in large amounts relative to the other viral proteins (88, 208) . However, nothing is known about the mechanism(s) that regulates the synthesis of this protein in infected cells. NS53 is a basic protein with a net positive charge of 9 at pH 7.0 on the basis of the deduced amino acid sequence (38) .
More recent analyses show that NS53 contains predicted zinc-binding sites between aa 54 to 66 and 314 to 327. Despite extensive sequence diversity between simian and bovine genes, these predicted metal-binding sites are conserved (D. B. Mitchell and G. W. Both, personal communication). These sites also appear to be functional on the basis of preliminary direct binding of zinc (Fig. 8) (102, 295) , but this was not demonstrated when the direct binding of radiolabeled nucleic acids to rotavirus proteins (immobilized on nitrocellulose filters) was evaluated (37) . Small amounts of NS53 have been detected in complexes isolated from infected cells associated with replicase activity (246) , and NS53 has been detected in protein complexes (in association with NS34 and RNA) that form following cell-free translation of mRNAs (K.-S. Au shown, and conserved cysteine (A) and proline (V) residues are highlighted as in Fig. 5 ; conserved hydrophilic (---) regions are also shown.
The two amino-terminal hydrophobic regions (Hi and H2), the methionine at the initiation codon used primarily in cells (*), the known site of cleavage of the signal peptide (arrow), the sites of potential glycosylation (boxes), the sites of sequence variation (dashed boxes), and the locations of known neutralization epitopes (A, B, and C) are also shown. The VP7 sequences of SAl1 as reported by Both degradation or toxicity necessitating the engineering of a fusion protein to express other proteins (9, 38, 219) .
Genome segment 5 possesses other unusual properties. Nucleic acid hybridization studies indicate that the nucleotide sequence of this gene may be the least conserved (101, 297) . In addition, genome segment 5 shows nonrandom reassortment when the distribution of individual segments which reassort in animals or in cells infected in vitro with two different rotavirus strains have been examined (4, 123) . The basis for this is currently unknown, but it suggests that certain gene 5 segments may be more favorable for replication. In addition, gene 5 has often shown genome rearrangements (158) . Taken together, these data suggest that NS53 may interact with genome segments during RNA replication or genome assortment.
A recent paper described an empty capsid-specific protein with a molecular weight of 55,000 (42) . Although the origin of this protein was not identified, the possibility that it is NS53 and that it is present only in empty capsids is an intriguing one. Perhaps NS53 is involved in packaging genomic RNA segments. It will also be interesting to determine whether any of the unusual properties of this gene are related to its containing the complementary sequence of the 3'-terminal consensus sequence internally.
NS35. NS35 is encoded by genome segment 7, 8, or 9, depending on the virus strain. For example, SAIl genome segment 8, RRV genome segment 9, and bovine UK virus genome segment 7 each encode this protein (123, 208, 217) . The deduced amino acid sequence of this protein indicates that it is basic, and immunocytochemistry experiments have localized this protein in association with viroplasms in infected cells (255) . These data and the fact that SAl group E temperature-sensitive mutants with mutations that map to this gene have an RNA-negative phenotype (267, 268) and produce a large proportion of empty particles (271) suggest that NS35 is involved in the replication of RNA or the packaging of ssRNA into subviral particles. The presence of a helix-turn-helix motif between residues 160 and 218 in this protein is consistent with possible interactions with nucleic acid. It will be of interest to determine whether these sequences are altered in the group E temperature-sensitive mutants. NS35 has been detected in subviral particles isolated from infected cells and characterized to possess replicase activity (145) . However, NS35 denatured and immobilized on nitrocellulose membranes did not bind to radiolabeled nucleic acids (37 (31) , and it is the one nonstructural protein that reacts with radiolabeled nucleic acids (RNA or DNA) on Western blots (37) . NS34 has consistently been found in complexes isolated from infected cells that contain replicase activity and in complexes formed in vitro in association with NS53 (Au and Estes, unpublished). Again, these data suggest that NS34 may be a component of the viral replicase (145, 247) , and, like NS35, further studies are required to define its precise role in the replication process.
NS28. The SAIl genome segment 10 product, NS28, is a nonstructural protein synthesized as a primary translation product of apparent molecular weight 20,000 and then cotranslationally glycosylated (88, 165) . The mature glycoprotein is an integral membrane protein of the ER. The amino terminus of this protein contains two sites where N-linked high-mannose oligosaccharides are added (Fig. 8) . The locations of these sites of glycosylation and biochemical analyses of the biosynthesis of this protein indicate that NS28 contains a noncleavable signal sequence (35, 88, 165) . Studies of the topography of NS28 indicate that the amino terminus of the molecule is maintained in the membrane and the carboxy terminus extends into the cytoplasm of infected cells (23a, 48) .
The cytoplasmic domain of NS28 has been proposed to be involved in the morphogenesis of virus particles that mature by budding through the membrane of the ER (89, 252) . NS28 has been proposed to act as a receptor to bind subviral particles (possibly single-shelled particles) and mediate their budding into the lumen of the ER (89, 166) . Glycosylation of NS28 is required for removal of the transient envelope from budding particles, because enveloped particles accumulate if infected cells are treated with tunicamycin (89, 149, 252) . The accumulation of such enveloped particles in cells treated with tunicamycin and infected with the variant containing the nonglycosylated VP7 proves that glycosylation of NS28 is critical for removal of the envelope (252) . Kinetic experiments have suggested that single-shelled particles are the precursors to double-shelled particles (166) , and a receptor role for NS28 is confirmed by the demonstration that purified single-shelled particles bind specifically to ER membranes containing only NS28 (13, 14, 222a) . Further studies of the function of this protein should be helpful to our understanding of the process of virus envelopment in general.
NS26. The identity of the protein product of genome segment 11 as a structural or nonstructural protein has remained unclear until recently. The primary translation product of the SAl gene 11 is a protein with an apparent molecular weight of 26,000 (88); the predicted molecular weight calculated from the gene sequence is 21,560 for the Wa virus (163, 345) and 21,725 for the SAIl virus (225, 349) . This protein was initially given a tentative assignment as a structural protein because it comigrated with a low-molecular-weight protein found in virus particles; however, lack of a high-titer antibody precluded direct proof of this assignment (88, 217) . Support for this assignment came from studies with reassortant viruses, which concluded that segment 11 codes for a minor neutralizing antigen (211) , and from the finding that the deduced amino acid sequence of this gene displays high sequence variation as expected for outer capsid structural proteins (345) . Others concluded this protein was nonstructural (11) .
The gene 11 protein is unusual in that it has a very high content of serine and threonine, with these amino acids being present in runs of three or four consecutive residues; these features share similarities with glycophorin (345) . Reexamination of the sequence of gene 11 shows that a second out-of-phase open reading frame is present that could code for a protein of 92 amino acids with a predicted molecular weight of 11,012 (225, 349) . No evidence exists yet on whether this second protein is produced, but conservation of its start and stop codons and predicted amino acid sequences in all strains sequenced to date are consistent with its being made.
Pulse-chase experiments showed that the gene 11 protein undergoes posttranslational modification following its synthesis (81, 88, 217 Fig. 3, 4 , and 6. In addition, the zinc-binding finger in NS53 (aa 54 to 56 and 314 to 327), known glycosylation sites for NS28 ( y ), potential locations of the ER membrane ( ?Z ), and regions of extremely high (1) and relatively high (1) sequence variation in NS28 and NS26 are shown. Compiled from sequences for the genes which code for these proteins (see Table 3 for references). threonine in this protein, it has been speculated that it might be modified by 0-linked glycosylation. However, attempts to directly confirm this hypothesis have not been successful (349) .
Synthesis of the gene 11 protein by using the baculovirus expression system has allowed the production of a high-titer antiserum, which has proved useful in experiments to readdress how the protein is modified and whether it is present in virus particles (349) . Definite demonstration that this protein is not a third outer capsid protein is important for investigators interested in making a subunit vaccine. Antibody to the baculovirus-expressed protein does not possess neutralizing activity, and it fails to react with virus particles as shown by immunoelectron microscopy, immunoblots, or immunoprecipitation. Instead, these studies indicate that the gene 11 protein is a phosphorylated nonstructural protein and that phosphorylation is not responsible for the mobility shift seen on polyacrylamide gels. The antibody to the baculovirusexpressed protein cross-reacts with viruses of all serotypes, showing discrete foci (viroplasms) in the cytoplasm of infected cells (112a, 349; E. Calomeni and M. K. Estes, unpublished data). This distinct staining could be used as a marker of virus replication.
The gene 11 segment is one of the segments often found to contain rearrangements (215, 250) (see above). Understanding the function of this protein might help us to understand why some segments (usually those encoding nonstructural proteins) undergo rearrangements during the replication cycle (see above). Reevaluation of the deduced amino acid sequences has shown that the high variation among the sequences of different viruses is due to a frameshift in the sequence of the Wa rotavirus at residues 123 to 132. Since this protein is nonstructural, the observed variability between the SAil and UK sequences in the region suggests that this domain is not essential for functioning of this gene. The presence of a potential mononucleotide-binding sequence (between Gly-31 and Ser-37) in gene 11 and its localization to viroplasms suggest that NS26 may be involved in RNA replication or gene reassortment.
GENE FUNCTIONS IN DIFFERENT STAGES OF VIRUS REPLICATION
The information on the structure of the proteins encoded by the viral genome provides a foundation for understanding the role of each gene in the replication cycle and in virus-NM M NH2 host interactions. Rotaviruses replicate almost exclusively in the differentiated enterocytes in the small intestine, and EM and immunocytochemistry studies of virus replication in intestinal biopsies or tissue sections indicate that the replication process determined from cell culture studies (primarily in monkey kidney cell lines) is similar in intestinal cells. The lack of direct studies of rotavirus replication in intestinal cells reflects difficulties in culturing specific intestinal cells; these difficulties were only recently overcome.
In monkey kidney cells, the replication cycle is fairly rapid, with maximum yields of virus being found after 10 to 12 h at 37°C when cells are infected with virus at high multiplicities (10 to 20 PFU per cell [63, 216, 266] ). Similar cycles are found for other virus strains, but the permissiveness of different types of cultured cells to rotavirus infection (and the cytopathogenicity of different virus strains) can vary (15, 57, 98, 132, 169) . These different cell lines can be expected to be studied further as efforts to identify the cell receptor and the mechanisms controlling virus-cell interactions expand. Rotavirus infection of cells presumably begins by interaction with a specific receptor, which probably is a sialic acid-containing protein, at least for the simian SAl rotavirus and the bovine NCDV rotavirus (19, 112a, 177, 357) . Human rotavirus strains, having different properties of hemagglutination and cell adsorption compared with some animal strains, may interact with a different receptor (112a). Whether subsequent virus entry (internalization) occurs by receptor-mediated endocytosis or direct penetration of membranes or both remains unclear (64, 169, 201, 253, 265, 321) . Understanding the functions of rotavirus proteins in the lytic replicative cycle also will facilitate identification of the cellular or viral factors that result in the establishment of persistent infections. The recent recognition that some (but not all) rotavirus strains cause hepatitis and death when administered to mice with severe combined immunodeficiency raises an immediate interest in identifying the gene(s) critical for this apparent altered viral pathogenesis and cell tropism (279) .
Current research efforts to develop new assays to probe the specific steps in the replication cycle based on the expression and interaction of individual proteins and RNAs in in vitro replication systems are expected to rapidly unravel details of the replication cycle. The separate stages of rotavirus replication are not considered here because they have recently been reviewed elsewhere (Estes, in press). However, new information on rotavirus morphogenesis is highlighted because this is such a unique step in the replication of these viruses (Fig. 9) . The sites of synthesis or localization of rotavirus proteins have been examined by ultrastructural immunocytochemistry with polyclonal monospecific antibodies or MAbs (254, 277) and by studying the distribution of proteins by immunofluorescence or in subcellular fractions (14, 166, 311, 349) . Most of the rotavirus structural proteins and nonstructural proteins are synthesized on the free ribosomes. This conclusion has been drawn on the basis of the lack of predicted signal sequences that would indicate targeting to the ER and the lack of protection of these proteins from digestion in in vitro protease protection studies (89, 165) , rather than on the basis of direct analyses of the nascent proteins on free ribosomes. In contrast, direct data show that the glycoproteins VP7 and NS28 are synthesized on ribosomes associated with the membrane of the ER and that they are cotranslationally inserted into the ER membrane owing to the signal sequences at their amino termini (89, 165 (164) . Regulation of transcription has been demonstrated by analyzing the mRNAs made in infected cells treated with cycloheximide. Under these conditions, mRNAs which encode NS53, VP6, NS35, and NS34 were seen. Much higher levels of mRNA which encode VP2 and NS35 also were found to accumulate in cells. Finally, the levels of mRNA present in cells were not directly reflected in the relative amounts of the corresponding protein made, and VP6 and NS28 were produced in large excess over the remaining nine proteins. An excess of minus-strand synthesis was also detected. These results suggest that the replication process is extremely inefficient, at least in cultured monkey kidney (BSC-1) cells.
The localization of several of the viral proteins (VP2, NS35, and NS26) to electron-dense viroplasms, the localization of VP4 and VP6 to the space between the periphery of the viroplasm and the outside of the ER, and the observation that particles emerging from these viroplasms often seem to directly bud into the ER that contains VP7 and NS28 indicate that the viroplasmic inclusions are probably the sites of synthesis of the single-shelled particles (255, 277) . Subviral particles form in association with viroplasms, and these precursor particles mature by budding through the membrane of the ER (5, 65, 78, 149) . In this process, or after budding, particles acquire their outer capsid proteins.
The morphogenic pathway of rotaviruses is distinctive in that subviral (probably single-shelled) particles, which assemble in cytoplasmic viroplasms, mature by budding through the membrane of the ER and that, during this process, particles possess a temporary envelope (Fig. 9) (for a review, see reference 78) . This is one of the most interesting aspects of rotavirus replication, and this unique feature distinguishes these viruses from other members of the Reoviridae family. The envelope acquired in this process is lost as particles move toward the interior of the ER, and ultimately, instead of the membrane, a thin layer of protein is found on the outer capsid of mature virions.
A kinetic study of the assembly of VP7 and of other structural proteins into particles was made possible by the ability to distinguish two pools of VP7 in the ER (166) . These two pools of VP7 can be separated biochemically by fluorocarbon extraction or by immunological methods (by using two classes of antibodies). One form of VP7, found only on intact particles, is detected only with a neutralizing MAb; a second pool of unassembled VP7 remains associated with the ER membrane and is detectable with a polyclonal antibody made to denatured VP7 (166) . The incorporation of proteins into single-shelled particles occurs rapidly, while VP4 and VP7 appear in mature double-shelled particles with a lag time of processing of the oligosaccharides on each form of VP7 has shown that the virus-associated VP7 oligosaccharides are processed with a 15-min lag compared with that of the membrane-associated form, suggesting that the latter is the precursor to virion VP7. This lag appears to represent the time required for virus budding and outer capsid assembly (166) .
Rotavirus maturation is apparently a calcium-dependent process, since it was observed that virus yields are decreased when produced in cells maintained in calciumdepleted medium (300) . In the absence of calcium, viruses produced are reportedly exclusively single shelled and budding of virus particles is not observed (299) . Reduced levels of only VP7 were observed owing to the preferential degradation (not to the impaired synthesis) of VP7 (299) . An interesting result in these studies was that unglycosylated VP7 made in the presence of tunicamycin (but not mature VP7) was relatively stable in a calcium-free environment. Unfortunately, the role of calcium in morphogenesis was not completely revealed by these studies. It is possible that calcium stabilizes or modulates folding or compartmentalization of the newly glycosylated VP7 for subsequent assem-VOL. 53, 1989 bly into particles or perhaps that calcium deprivation destabilizes the ER or other ER proteins required for the stable association of glycosylated VP7 with the membrane.
The infectious cycle ends with the release of progeny virus by cell lysis, as observed by thin-section EM (5, 55, 221 (350) . Identification of the site of cleavage in VP7 as occurring after residue 50 indicated that both amino-terminal hydrophobic domains are removed from the mature protein (257, 316) . Since VP7 normally remains anchored after processing, these results implied that residues distal to residue 50 (i.e., the region from aa 51 to 61 that was present in wild-type VP7 but missing from the secreted mutant lacking aa 47 to 61) must be involved in retaining VP7 in the ER. The initial conclusion that the H2 domain itself contained the ER retention information thus required modification.
Instead, these seemingly conflicting results are consistent with the idea that aa 47 to 61 might be necessary, but not sufficient, for ER retention. This idea has been tested directly by studying the expression and secretion of chimeric genes (257, 315 (257) .
A study of a second series of VP7-amylase chimeras in which the VP7 contribution extended to aa 111 resulted in retention of amylase within the ER, and this protein retained enzymatic activity. These results, therefore, suggested that two regions of VP7 mediate its retention in the ER. The first lies within the region spanning aa 51 to 61, and the second lies in the region spanning aa 62 to 111, the latter containing the single glycosylation site for VP7. Both regions are apparently necessary for retention, although neither by itself is sufficient for retention (257) .
Different conclusions on the residues of VP7 needed for ER retention were reached in an independent study in which amino acid residues 30 to 64 of VP7 were exchanged with the signal peptide from the influenza virus hemagglutinin (315) . These constructs, which maintained the usual cleavage site for VP7, caused secretion of VP7. Because these HAF VP7 constructs contained both regions (aa 51 to 61 and 62 to 111) proposed (as described above and in reference 257) to be necessary for VP7 retention, these regions alone are clearly not sufficient for VP7 retention. Studies with other chimeric proteins indicate that interactions between the cleaved signal peptide (the H2 domain) and other downstream sequences in VP7 are required, directly or indirectly, for retention of this protein in the ER membrane (315) . This is the first demonstration of a function for a cleaved signal peptide.
The method by which VP7 is retained in the ER remains an interesting question. VP7 does not contain the discrete peptide Lys-Asp-Glu-Leu, which was recently found to confer retention of other proteins to the ER (226) . The topography of VP7 in the membrane also is not well understood. Based on its resistance to digestion with proteolytic enzymes, VP7 is not a membrane-spanning protein (89, 165) . However, VP7 is membrane associated since it remains membrane bound after high-salt treatment and release of its microsomal contents at high pH by sodium carbonate treatment (165) . It is possible that VP7 is retained in the ER by conformational properties that mediate membrane attachment or by oligomerization with itself or other specific cellular proteins.
These analyses of processing of VP7 with gene 9 mutants produced by site-directed mutagenesis show the power of this approach to the correlation of gene structure and function. (257, 316) . These results are of interest for investigators using strategies to produce authentic VP7 in expression vectors for testing as potential vaccines (see below), and they also reemphasize the puzzling question of why both initiation codons that each precede a hydrophobic domain are retained in all VP7 genes sequenced so far. Comparisons of the amino acid sequences of VP7 are striking when the conserved and variable amino acids found upstream of the cleavage site prior to Gln-51 are examined. The first 8 aa of VP7, both initiation codons, leucine 23 and lysine 25 at the end of the Hi domain, and glutamine 51 following the H2 domain (and shown to be the major site of cleavage of the mature protein) are strictly conserved. These conserved regions are consistent with the idea that both initiation codons are used. In contrast, extensive variation is seen in the H2 domain (Fig. 6) . One wonders what factors cause such variation in this domain. Perhaps these changes compensate for changes downstream in other amino acids (between aa 62 and 111) with which H2 may interact (257, 315) .
Analysis of the synthesis and expression of a series of altered gene 10 cDNAs has been used to localize the sequences involved in translocation of the nonstructural glycoprotein NS28. A series of mutations in the coding regions for the three hydrophobic domains (Hi, H2, and H3) of this protein were constructed and analyzed by in vitro translation and by transfection in vivo. In vitro, all three hydrophobic domains associated with microsomes. However, glycosylation and proteolysis of wild-type and mutant forms of NS28 indicate that the wild-type protein is anchored in the membrane only by the second hydrophobic domain, leaving approximately 131 residues exposed on the cytoplasmic side of the membrane (23a). These studies extended initial studies on the topology of NS28 in microsomal membranes (48) by suggesting that the cytoplasmic domain is larger than originally thought and by proposing a model in which the second (H2) hydrophobic domain is the membrane-spanning domain rather than the third (H3) as proposed earlier. Although both papers confirm that the H3 domain is protected from digestion with various proteases, analyses of the mutant molecules indicate that protease sites upstream of the H3 domain are available for cleavage. It is therefore concluded that H3 is merely resistant to cleavage by being embedded or protected by interactions with the cytoplasmic side of the membrane (23a). Site-directed modification of the cytoplasmic domain of the protein will no doubt help to better define the domains of NS28 involved in receptor-ligand interactions.
Studies of the processing of the oligosaccharides on the rotavirus glycoproteins have also been useful in probing the types of oQ-mannosidases specific to the RER. Initial pulsechase experiments showed that the oligosaccharides on the rotavirus glycoproteins are trimmed (89, 165) ; Man8GlcNAc2 and Man6GlcNAc2 were found to be the predominant intracellular species detected after a 5-min pulse with [3H]mannose and a 90-min chase, and VP7 on mature virus was processed to Man5GlcNAc2 (165) . Although removal of the outer glucoses and at least one mannose residue had been shown to occur on nascent chains of vesicular stomatitis virus G protein in the RER (12) , the location, linkage specificity, and total number of the different o2-mannosidases acting during the remaining processing reactions were not previously clear. Evidence had been presented for both RER and Golgi apparatus activities (156) . In contrast, the subsequent steps of carbohydrate modification, including the addition of N-acetylglucosamine residue, removal of cxl,3-and a.1,6-mannoses, and transfer of terminal sugars, were known to be localized to the Golgi complex (104) . Studies tion of reassortants was observed with specific pairs of parental viruses. Therefore, selection of specific reassortants following coinfection is apparently due to differences in the infectivities of progeny viruses and not in their assembly. This implies that reassortant infectivity is a function of the parental origin of specific genomic segments and that selection of surviving reassortants appears to occur because certain reassortants grow better than other reassortants (123, 348) .
Reassortment of genome segments among the progeny of in vitro mixed infections has been exploited to derive reassortant viruses with a desired subset of genome segments from each parent. Such reassortants have been used to correlate functions with specific genome segments. In addition to allowing the assignment of temperature-sensitive mutants to a specific genome segment, this powerful approach has identified a number of biologic properties that cosegregate with specific genome segments (reviewed above and below). This genetic approach to probing gene function will continue to be used to map phenotypic differences that are identified between two parental viruses in the future.
Characterization of the progeny of cells coinfected with two strains of rotaviruses has shown that phenotypically mixed viruses (pseudotypes and mosaics of the capsid protein VP7) readily form. This was demonstrated by showing that the progeny were able to be neutralized by MAbs specific for the VP7 of each of the coinfecting strains (347) . This result has practical implications, because it suggests that selection of reassortants (containing specific VP4 and VP7 proteins) by using neutralizing antibodies may be of little value unless these antibodies are added only to the overlay agar during plaque formation.
Recent studies in which reassortants were used to map biologic properties of rotavirus genome segments have shown that the criteria needed for firm conclusions from studies with reassortants are more rigorous than formerly realized. For example, early studies which examined the gene segments responsible for inducing neutralizing antibody identified only one genome segment (8 or 9, depending on the virus strain) with this property, but in those studies no reassortants containing a gene segment 4 from a human virus was able to be cultivated and characterized (138) . Subsequent studies revealed that genome segment 4 also possesses this property, and this highlights the importance of analyzing reciprocal reassortants when using the genetic approach for phenotypic mapping.
In addition, unknown common properties of parental viruses may influence the interpretation of genetic studies of reassortant viruses. For example, two bovine viruses (UK and NCDV) were eventually found to possess related VP7 antigens, but their VP4 antigens are distinct (139a, 153) . Therefore, properties related only to the distinct genome segment 4 of each of these two parental viruses would be able to be dissected by reassortant analyses. Since the common properties of parental viruses may not be known in advance, it is useful to confirm results by using different parental strains. The identity of naturally occurring intertypic rotavirus strains (152, 153, 214, 224) and the direct demonstration that rotavirus genes reassort at high frequency in vivo (123) and in vitro (131, 138, 266) highlight the fact that the genetic background of any rotavirus isolate cannot be assumed. This point has been further illustrated in recent analyses of reassortants which indicate that the phenotype of specific reassortants is altered depending on the parental strain used for analysis (56 (140) , and studies with other older animals (rabbits, calves, and gnotobiotic piglets) are also possible with several cultivatable virus strains (69, 151, 334, 355) .
Genome segment 4 has also been implicated to be important in virulence on the basis of comparisons of the amino acid sequences of viruses originally isolated from newborn babies with asymptomatic infections and older babies with symptomatic infections (126, 127) . Further studies are required to determine the validity of this hypothesis and to determine the relative roles of host and viral factors in determining whether infections of newborns (and older children) result (209, 243) .
Several studies have raised doubts about the importance in protection of the differences in neutralization antigens measured by in vitro plaque reduction assays, and mechanisms other than neutralizing antibody have been proposed to be important in protection. Initial studies failed to show heterotypic protection in gnotobiotic calves (354 Epidemiologic studies showing the significant mortality and morbidity caused by rotavirus disease in individuals in developing and developed countries, respectively, focus the need for an effective vaccine. Since life-threatening and clinically significant disease occurs in children less than 2 years of age, current vaccines are aimed at preventing clinically significant diarrhea (and not infections) in this target population. The first vaccines to be tested in children have been live vaccines, because they are expected to induce more effective local mucosal immunity and greater duration of immunity than killed vaccines (52, 86, 175, 343) .
The initial live candidate vaccines to be developed have been from animal strains. Three candidate vaccines (RIT 4237, a bovine serotype 6 virus; RRV MMU 18006, a rhesus monkey serotype 3 virus; and WC3, a bovine serotype 6 virus) have progressed to field trials. These vaccines are not representative of the most common serotypes found in humans, but they were developed with the assumption that heterotypic immunity would provide protection from disease with human viruses (175) . The bovine strain (RIT 4237) showed good efficacy when tested initially in developed countries, but failed to provide protection when tested in developing countries; it has now been removed from further testing (351) . A subsequent field trial of RIT 4237 in L ma, Peru, showed that this vaccine afforded 58 to 75% protection against the more severe rotavirus illness if given in more than one dose, and better protection was found against disease caused by serotype 1 viruses than by serotype 2 viruses (191) . This vaccine trial provided important insights by defining the requirements for performing a successful vaccine trial in a developing country (191) . It also highlighted the need to provide protection against multiple rotavirus serotypes and the possible need for multiple doses to obtain adequate protection. Surprisingly, most vaccine trials have been performed in areas where the natural challenge viruses were of one or two serotypes. Increasing information on the geographical distribution and changes in the prevalence of rotaviruses indicates that it will not be possible to predict which serotype(s) will be more common at a given time in a given geographical location (342a; Matson et al., submitted). Because of this, none of the current vaccine candidates have really been given a thorough evaluation, and possibly a live polyvalent vaccine will be necessary to account for expected changes in serotype distribution.
The RRV MMU 18006 vaccine has undergone fairly extensive testing. It has been shown to be immunogenic and slightly reactogenic, and it has shown efficacy in field trials to natural infections with serotype 3 challenge but not serotype 1 challenge (52) . These results, together with the previous studies of the RIT 4237 vaccine, suggest that serotype-specific immunity may be required for satisfactory protection against rotavirus diarrhea. This conclusion agrees with epidemiologic data, which showed that natural protection against rotavirus gastroenteritis is related to concentrations of serum antibody against homotypic virus and that the levels of heterotypic antibodies are generally below the threshold level needed for protection (58) . Studies of the active immune response in known seronegative animals also indicate that the primary neutralizing immune response is homotypic (93, 310) . This suggests that demonstration of heterotypic responses in vaccinated children may reflect measuring responses in children who had been previously primed by unrecognized infections (93, 309) or who are infected by a virus strain whose outer capsid proteins contain epitopes shared by several other virus strains (73) .
Preliminary efficacy testing of the bovine WC3 vaccine showed that this virus strain provided protection against disease with heterologous human serotype 1 virus infections when tested in the United States (60) . These results are promising (as were the initial RIT 4237 trials), and only additional field trials will determine whether this vaccine will prove efficacious in other settings, including developing countries. If it does, further characterization of this bovine virus strain will be of interest to determine the mechanism by which it induces heterotypic protection.
Other approaches to developing candidate vaccines are under way. Reassortants containing a single gene which codes for the outer capsid glycoprotein from human virus serotypes on a rhesus rotavirus background have been produced as possible candidate vaccines to induce homotypic immunity to the four human serotypes (223) . These strains are now in phase I trials to evaluate their reactogenicity and immunogenicity and to determine whether administration of a polyvalent vaccine will affect "takes" of individual strains (109, 143) .
The possibility that viruses that have become endemic in neonatal nurseries are attenuated, because they cause asymptomatic infections, and that they might be useful as human virus vaccine strains is also being considered. This idea is based on an epidemiologic study showing that children infected with these strains as neonates had no severe disease with subsequent rotavirus infections during their first 2 years of life (28) . Therefore, neonatal vaccination with such strains may induce protective clinical immunity. However, there is currently no direct evidence from studies in animal models or volunteers that these viruses are actually attenuated. This idea needs further confirmation, since other recent studies suggest that reinfections may give rise to an equally or even more severe illness (193) .
The availability of cDNA copies of many of the rotavirus genes has opened the possibility of using live expression vectors or subunit vaccines of individual proteins synthesized from these clones as recombinant vaccines. Possible approaches have been discussed elsewhere (33, 95) . The rotavirus outer capsid proteins (VP4, VP7) have been expressed alone or as fusion products using bacterial expression systems (8, 9, 110, 219) . Expression of about 45% of the SAl VP4 in a thermoinducible expression system resulted in the synthesis of hybrid MS2 polymerase-VP4 protein which was antigenic on the basis of immunoblot reactivity with hyperimmune guinea pig anti-SAl serum. Immunization of mice with this fusion protein induced antibodies which neutralized virus with a mean titer of 1:1,200. Although these titers were at least 20 times lower than those obtained following immunization with complete virus particles, the hemagglutination inhibition titers in each type of serum were similar. Heterotypic neutralization titers were not reported. The synthesized protein was aggregated, and it is not known whether this had an effect on the immunogenicity of this protein. VP4 Several different constructs of VP7 have been expressed in bacteria (8, 110, 219) . VP7 expressed alone was toxic (219), whereas VP7 expressed as a fusion protein with 3-galactosidase was not. Neutralizing antibody of relatively low titer (1:100 to 1:1,600 for SAIl VP7 [8] ; 1:300 for UK bovine VP7 [219] ) has been induced, but antibody to expressed NCDV VP7 did not possess neutralizing activity (110) . Examination of the immunogenicity of VP7 produced by using a vaccinia virus expression system indicated that neutralizing antibodies with low titers (1:40 to 1:640) were induced and that these were serotype specific when tested in plaque reduction assays or by ELISA (6) . In immunoblots these sera reacted with denatured VP7 from serotypes 1, 3, and 4, and the lack of reactivity with serotype 2 was suggested to be due to blocking of a possible cross-reactive site at aa 149 by carbohydrate in these viruses.
A high-yielding baculovirus expression system has also been used to successfully produce 9 of the 11 rotavirus gene products (94, 202; Cohen and Estes, unpublished). The proteins synthesized in this system possess native conformation on the basis of reactivities with available MAbs and polyclonal antibodies and biochemical comparisons with their authentic counterparts made in mammalian cells. VP6 expressed alone forms trimers and capsomerlike structures (94) . Neutralizing antibody is induced by immunization of guinea pigs with VP7 (Estes, unpublished). Future efforts will determine whether an effective subunit vaccine can be produced by immunization with these antigens singly and in combination. Since none of the expressed proteins induce neutralizing antibodies with equivalent titers to those produced by immunization with viral particles, it is possible that combinations of proteins will be required to achieve proper conformation and the best vaccination results.
Successful expression of the rotavirus proteins is only the first step toward making an effective subunit vaccine to protect against rotavirus gastroenteritis. The following challenging questions must now be considered. (i) Will it be possible to induce a protective mucosal immunity by oral vaccination with a nonreplicating antigen? (ii) Can novel delivery systems or adjuvants be established to ensure proper antigen presentation in the gastrointestinal tract? (iii) Can long-lasting immunity be induced? (iv) Can subunit vaccines safely and effectively immunize malnourished and/ or immunocompromised children who normally may develop persistent infections?
The potential for improving the immunogenicity of expressed rotavirus peptides has already been demonstrated by including peptide determinants known to induce T helper cells in mice (30) . Knowledge of the specific rotavirus proteins that induce intestinal cytotoxic T cells and stimulate the uptake of viral antigen by Peyer's patches and knowledge of the role of cell-mediated immunity in protection against, recovery from, or pathogenesis of rotavirus disease may permit the stimulation of more rapid recovery from infection. Studies addressing these questions have been initiated (76, 242, 278) . Future studies addressing these questions and the testing of live expression vectors to deliver antigens directly to the gastrointestinal tract are expected to be fruitful.
Passive Immunization Alternative approaches to active vaccination to prevent rotavirus gastroenteritis are also being considered. In animals in which the young receive immunoglobulins from colostrum and milk instead of by transplacental transfer, vaccination of dams can raise colostral antibody levels to sufficiently high titers that the young animals are passively protected through the time of maximum sensitivity to infection (289) . Success has been achieved with this approach in calves (22a, 290, 308). It has clearly been shown that in these animals, vaccination with live or inactivated vaccines boosts the immune response in naturally primed animals, and the resulting heterotypic lactogenic immune response has been shown to be dependent on the preexposure history of the animals (43, 309) . Because of the expected lower cost of production and safety testing of subunit vaccines and the ability to use inactivated and heterologous viruses to boost lactogenic immunity, testing of the available expressed proteins in such systems may be worthwhile.
The possibility of ameliorating rotavirus infections in children by the administration of cow's milk containing such heterotypic antibodies is also being evaluated. Although such treatments will not be recommended in developing countries, where breast-feeding needs to be encouraged, they have been used to stop prolonged rotavirus excretion in immunocompromised and normal children (146, 198) . Although it remains unclear whether such therapy will significantly decrease the incidence of diarrhea in immunocompetent children, it is possible that such treatment will be useful in certain settings (e.g., day-care centers) where diarrhea is a continuing problem and decreased shedding might help prevent transmission.
CONCLUDING REMARKS
The new information learned about the structure and function of rotavirus genes and their proteins in the last 5 years is impressive in its amount and its significance in helping to understand the epidemiology, pathogenesis, replication, and molecular biology of these viruses. Future studies to understand how trypsin cleavage mediates the selective internalization of the viral capsid into cells and how the nonstructural proteins function in the replication cycle should elucidate the mechanisms by which the virus replicates and encapsidates one of each of its 11 genome segments into nascent particles. This information, in turn, may allow the manipulation and encapsidation of any RNA segment. Further studies of rotavirus morphogenesis should help clarify the virus-budding process in general. With the fundamental information on the structure of the genes and their proteins reviewed here, research efforts can be directed toward unraveling the biology of these viruses and their interactions with the hosts they infect. Studies to identify the cellular receptor, to dissect the immune or nonimmune responses to specific proteins that are important for a protective immune response, and to learn how to induce these responses can be expected. Finally, further studies of the properties of viruses that circulate over time or that reinfect children should shed light on how these viruses evolve and help determine whether this evolution will complicate needed vaccination programs.
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